rcom default

Sanofi-Regeneron’s Praluent cuts cholesterol in Odyssey trials | Reuters

Posted on

PARIS France’s Sanofi and companion Regeneron Prescription drugs stated on Sunday their anti-cholesterol drug Praluent recorded constructive leads to its first devoted studies involving sufferers with diabetes and excessive cholesterol.

Praluent considerably lowered low-density lipoprotein cholesterol in two part 3b/4 Odyssey trials, the businesses stated in a joint assertion.

Other articles you might like;

Leave a Reply

Your email address will not be published. Required fields are marked *